Article

New Asthma Drug Gets Good Reviews

Author(s):

Adding tiotropium bromide inhalation spray to asthma therapies improved lung function, symptom control, and also reduced flare-ups, studies have found.

Adding tiotropium bromide inhalation spray (Spiriva, Respimat/Boehringer Ingelheim) to other asthma therapies improved lung function and symptom control and reduced flare-ups, studies presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting is Los Angeles, CA found.

Summarizing the studies’ results in a news release the company quoted one investigator.

“The data confirm that adding SPIRIVA® RESPIMAT® is a well-tolerated and effective treatment option for asthma patients independent of allergic subtype,” said Mark Vandewalker, MD, director, Clinical Research of the Ozarks, Columbia, MO.

“For people with allergic asthma who are still experiencing symptoms, adding SPIRIVA® RESPIMAT® may help open airways to improve breathing.” Vandewalker said.

His study is here.

The drug is a new class of inhaled medicine and it is non-steroidal.

It is given long term, once daily as a prescription maintenance treatment for patients age 12 and older.

It is not a rescue medicine however.

There are several studies that contributed to the findings. They can be found on the meeting’s abstracts page by searching “tiotropium.”

Related Videos
How to Manage Aspirin-Exacerbated Respiratory Disease
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
MeiLan Han, MD: Discussing Updates on Dupilumab, Ensifentrine in 2025 GOLD Report
Physician, Patient, and Partner Perspectives on AERD with Mitchell Grayson, MD, Rhonda Nelson, and Wayne Nelson
Monica Kraft, MD: Discussing Phase 3b Findings on Albuterol/Budesonide for Asthma
How Artificial Intelligence is Being Used in Lung Imaging, with Rachel Eddy, PhD
Developing Risk Assessment Tools for Viruses in School
Using Microbiomes to Diagnose Ventilator-Associated Pneumonia
What Do Patients Need to Learn About their Hypersensitivity Pneumonitis?
© 2024 MJH Life Sciences

All rights reserved.